Showing 1901-1910 of 2736 results for "".
- Allergan Aesthetics and Skinbetter Science Launch The DREAM Initiative to Advance Health Equity and Diversity in Aestheticshttps://modernaesthetics.com/news/allergan-aesthetics-and-skinbetter-science-launch-the-dream-initiative-to-advance-health-equity-and-diversity-in-aesthetics/2472990/Allergan Aesthetics, an AbbVie company, and Skinbetter Science have jointly launched a new long-term, educational initiative—DREAM: Driving Racial Equity in Aesthetic Medicine. The DREAM Initiative™ is committed to furthering the principles of racial and ethnic diversity, inclus
- Consumer Products Vet Anne Gates Joins Cynosure's Board of Directorshttps://modernaesthetics.com/news/consumer-products-vet-anne-gates-joins-cynosures-board-of-directors/2472989/Anne Gates, former President at MGA Entertainment and Executive Vice President and CFO of The Walt Disney Company's Consumer Products Division, has joined Cynosure’s board of directors and will chair the company's audit committee. "Anne brings with her a wealth o
- NYC Dermatologist Dr. Doris Day Joins Nufabrx’s Ad Boardhttps://modernaesthetics.com/news/nyc-dermatologist-dr-doris-day-joins-nufabrxs-ad-board/2472988/New York City dermatologist Doris Day, MD is the newest member of Nufabrx’s advisory board. Nufabrx is an advanced textiles company that has developed a proprietary biomaterial platform that embeds active ingredient
- Revance Commercial Infrastructure to Roll Out RHA Collection of Dermal Fillershttps://modernaesthetics.com/news/revance-commercial-infrastructure-to-roll-out-rha-collection-of-dermal-fillers/2472985/Revance Therapeutics, Inc. will begin introducing the RHA Collection of dermal fillers, Resilient Hyaluronic Acid, and the HintMD financial technology platform, in the United States in September. The RHA Col
- Estée Lauder and Atropos Therapeutics Team Up to Discover Senomodulatorshttps://modernaesthetics.com/news/estee-lauder-and-atropos-therapeutics-team-up-to-discover-senomodulators/2472980/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify a
- Galderma Donates 1,200 Backpacks Filled with School Supplies to Northwest ISD Studentshttps://modernaesthetics.com/news/galderma-donates-1200-backpacks-filled-with-school-supplies-to-northwest-isd-students/2472977/For the fifth consecutive year, Galderma donated backpacks filled with school supplies to Northwest Independent School District (NISD) students. This year, Galderma donated 1,200 backpacks for students in grades Kindergarten through 12, for a total of 6,105 backpacks donated since 2016.
- NYC Plastic Surgeon Dr. Sachin Shridharani Joins Soliton’s Scientific Advisory Boardhttps://modernaesthetics.com/news/sachin-shridharani-md-joins-solitons-scientific-advisory-board/2472973/Sachin Shridharani, MD has joined Soliton, Inc’s Scientific Advisory Board. Soliton, Inc. recently filed for 510(k) premarket clearance with the U.S. Food and Drug Administration (FDA) of its second-generation Rapid Acoustic Pulse (RAP) device for the reduction in the appearance o
- Allergan Donates $300K to Bridge the Gender Gap in STEMhttps://modernaesthetics.com/news/allergan-donates-300k-to-bridge-the-gender-gap-in-stem/2472964/Allergan has pledged $300K to support STEM Education through their partnership with Girls Inc. In addition to the donation, Allergan is also offering mentoring initiatives and resources to educate and empower future female leaders interest
- Revance’s DaxibotulinumtoxinA for Injection Looks Good in Phase 2 Studies of Forehead Lines and Crow’s Feethttps://modernaesthetics.com/news/revances-daxibotulinumtoxina-for-injection-looks-good-in-phase-2-studies-of-forehead-lines-and-crows-feet/2472963/Revance Therapeutics, Inc.’s next-generation neuromodulator product, DaxibotulinumtoxinA, safely and effectively smoothed forehead lines and Crow’s feet with a median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet achieved in at least one treatment group
- Abbvie’s Allergan: 1, Evolus: O in First Round of Trade Disputehttps://modernaesthetics.com/news/abbvies-allergan-1-evolus-o-in-first-round-of-trade-dispute/2472962/Evolus' and Daewoong Pharma's Jeuveau lost the first round in a trade dispute with AbbVie's Allergan and its Korean partner Medytox that sought to block imports of the Botox rival, but the match is not over yet. AbbVie's Allergan and its Korean partner Medytox